Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,048

Dr. Keith Sumption, Ph.D. — Chief Veterinary Officer — Food and Agriculture Organization of the UN

One Health Approaches To Prevent Zoonoses & Antimicrobial Resistance — Dr. Keith Sumption, Ph.D. — Chief Veterinary Officer and Leader of the Animal Health Program; Director, Joint Centre for Zoonoses and Anti-Microbial Resistance (CJWZ), Food and Agriculture Organization of the United Nations (FAO)

Dr. Keith Sumption, Ph.D. is Chief Veterinary Officer and Leader of the Animal Health Program at the Food and Agriculture Organization of the United Nations (FAO — https://www.fao.org/home/en) as well as their Director of the Joint Centre for Zoonoses and Anti-Microbial Resistance (CJWZ).

The Food and Agriculture Organization of the United Nations is an international organization that leads international efforts to defeat hunger and improve nutrition and food security. The FAO comprises 195 members and helps governments and development agencies coordinate their activities to improve and develop agriculture, forestry, fisheries, and land and water resources. It also conducts research, provides technical assistance to projects, operates educational and training programs, and collects agricultural output, production, and development data.

Dr. Sumption has worked on disease ecology at the interaction of wildlife, domestic and the environment for more than 30 years.

Dr. Sumption holds a Doctor of Philosophy (PhD) from the University of Reading, gained following 3 years of field and molecular epidemiology research upon African Swine Fever in southern Africa, and veterinary medicine (Vet. MB) and Natural Sciences degrees from the University of Cambridge in the United Kingdom.

Continue reading “Dr. Keith Sumption, Ph.D. — Chief Veterinary Officer — Food and Agriculture Organization of the UN” | >

Forget AI, organoid intelligence could take computing to the next level

A new concept called organoid intelligence, with the aim of developing a new generation of biocomputers, has recently been detailed by a group of researchers. They want to harness advances in the reproduction of human brain cells in vitro to offer superior intelligence to the computers and smart devices of the future. This technology promises to be much more powerful and efficient than any form of artificial intelligence as we know it.

This notion of organoid intelligence is described in a paper outlining a roadmap to developing this technology published in the journal Frontiers of Science, by numerous scientists, mainly from Johns Hopkins University in Baltimore. According to them, work on cerebral organoids, derived from human stem cells, should make it possible in the relatively near future to reproduce entities endowed with memory and a genuine capacity for learning. Organoids are miniature organs grown in vitro. The term organoid intelligence (OI) encompasses all these developments, leading to a form of biological computing — or biocomputing — that leverages neurons bred in a lab. All of which is enough to make the likes of ChatGPT seem outdated already.

Complex interfaces could eventually be networked, with brain organoids connected to sensory organoids such as retinal organoids. This could, for example, lead to new therapeutic applications.

Joel Greshock — VP, Oncology, Data Science & Digital Health — Janssen Research & Development

Driving Toward the Elimination of Cancer — Joel Greshock — VP, Oncology, Data Science & Digital Health, Janssen Pharmaceutical Companies of Johnson & Johnson.

Joel Greshock is VP, Oncology, Data Science & Digital Health, Janssen Research & Development (https://www.janssen.com/oncology/leadership-team). In this position, he is responsible for creating unique and actionable medical insights using large and increasingly available datasets. The focus of this research includes discovering novel therapeutic targets, identifying areas of unmet medical need, and enhancing clinical trial recruitment and execution.

Prior to joining Janssen R&D, Joel served as Vice President of Bioinformatics at Neon Therapeutics, Inc., where he built and managed the Data Sciences organization. At Neon, he was responsible for the design and deployment of personalized cancer therapies now under clinical evaluation.

Prior to joining Neon, Joel served as Head of Oncology Translational Informatics for Novartis, where he was responsible for the correlation of patient outcomes with molecular biomarkers, identification of mechanisms of clinical resistance and computational research for assets approaching or being evaluated in early phases of development.

Before joining Novartis, Joel assumed numerous roles for GlaxoSmithKline Oncology, which included Head of Bioinformatics. Earlier in his career, Joel was a Data Analyst at Abramson Family Cancer Research Institute at the University of Pennsylvania, where he built early generation microarray platforms and developed widely used predictive models for cancer predisposition mutations.

Continue reading “Joel Greshock — VP, Oncology, Data Science & Digital Health — Janssen Research & Development” | >

6 Theories About What Lies Outside The Observable Universe!

https://youtube.com/watch?v=uYjjRAcI7x4&feature=share

For copyright contact: stienlemane2379(at)gmail.com.

Welcome to Futureunity, where we explore the fascinating world of science, technology, and the universe! From the inner workings of the human body to the outer reaches of space, we delve into the latest and most interesting discoveries that are shaping our world. Whether you’re a science buff or just looking for some mind-blowing facts, we’ve got you covered. Join us as we uncover the mysteries of the world around us and discover new frontiers in the fields of science and technology. Get ready for a journey that’s both educational and entertaining!

Disclaimer Fair Use:
1. The videos have no negative impact on the original works.
2. The videos we make are used for educational purposes.
3. The videos are transformative in nature.
4. We use only the audio component and tiny pieces of video footage, only if it’s necessary.
Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education, and research. Fair use is a use permitted by copyright statutes that might otherwise be infringing.

Disclaimer:
Our channel is based on facts, rumors & fiction.

Immediate complete revascularization found to be as safe, effective as staged procedure in treating multi-vessel disease

In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents in all diseased arteries was found to be as safe and effective at one year of follow-up as staged treatment, according to findings from the first large, randomized trial to address this question that is being presented at the American College of Cardiology’s Annual Scientific Session Together With the World Congress of Cardiology. In staged treatment, the blocked artery that caused the heart attack is treated with a stent immediately and other partially blocked arteries are treated in a second procedure up to six weeks later. This study was simultaneously published online in The Lancet at the time of presentation.

About half of patients who have a have multi-vessel heart disease—this means that in addition to having one completely blocked that caused their heart attack, they have additional narrowed coronary arteries that are at risk of becoming blocked or unstable, leading to another heart attack. Clinicians refer to the blocked artery that causes a heart attack as the “culprit lesion” and to the other at-risk arteries as “non-culprit lesions.”

“The purpose of the international, randomized BIOVASC trial was to compare outcomes for immediate and staged complete for patients with multi-vessel heart disease who have suffered a heart attack. The goal was not to determine which approach was superior but rather to establish whether immediate complete vascularization was ‘not inferior’ to the staged approach, which needed to be answered first,” said Roberto Diletti, MD, Ph.D., an interventional cardiologist at Erasmus Medical Center in Rotterdam, Netherlands, and lead author of the study.

Starlink faces competition, OneWeb one launch away from global internet

The firm faced financial collapse during the pandemic but is now serving customers in 15 countries.

U.K.-based OneWeb is one launch away from having enough satellites in orbit to cover the entire expanse of the Earth. Once ready, Elon Musk’s Starlink won’t be the only company offering such as service, the BBC

Both OneWeb and Starlink use constellations of satellites in low Earth orbits (LEO) instead of the conventional geostationary orbits (GEO). The lower altitude of the LEO satellites helps in reducing latency or the delay that data takes to make a round trip over a network.

1, 2

The Limits of Computing: Why Even in the Age of AI, Some Problems Are Just Too Difficult

Empowered by artificial intelligence technologies, computers today can engage in convincing conversations with people, compose songs, paint paintings, play chess and go, and diagnose diseases, to name just a few examples of their technological prowess.

These successes could be taken to indicate that computation has no limits. To see if that’s the case, it’s important to understand what makes a computer powerful.

There are two aspects to a computer’s power: the number of operations its hardware can execute per second and the efficiency of the algorithms it runs. The hardware speed is limited by the laws of physics. Algorithms—basically sets of instructions —are written by humans and translated into a sequence of operations that computer hardware can execute. Even if a computer’s speed could reach the physical limit, computational hurdles remain due to the limits of algorithms.

First longevity clinical study design fetches FDA approval

Loyal, a clinical-stage veterinary medicine company developing drugs intended to extend the healthspan and lifespan of dogs, has announced it has received protocol concurrence from the FDA for its companion dog longevity study.

Longevity. Technology: Loyal is on a mission is to help dogs everywhere live longer, healthier lives – and that means taking on the development of the first FDA-approved drugs explicitly intended to extend lifespan and healthspan. On the path to FDA approval, Loyal must run a clinical trial that objectively and robustly demonstrates that its drug extends dogs’ healthy lifespan – and does so safely. However, no-one has developed a dog – or human – longevity drug before, so Loyal is building the path to FDA approval largely from scratch.

Today, Loyal has announced that last week it learned from the FDA that the company has received protocol concurrence for its companion dog longevity study. This is good news for the longevity biotech sector, especially welcome as it comes on the same day that tech lender Silicon Valley Bank collapsed and was put under the control of the US Federal Deposit Insurance Corporation – news that left biotechs and VCs reeling.

Reduced Blood Pressure: Was It Caused By Lung Muscle Training?

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Use Code: ConquerAging At Checkout.

Green Tea: https://www.ochaandco.com/?ref=conqueraging.

Oral Microbiome: https://www.bristlehealth.com/?ref=michaellustgarten.

Epigenetic Testing: https://bit.ly/3Rken0n.
Use Code: CONQUERAGING!

At-Home Blood Testing: https://getquantify.io/mlustgarten.

Continue reading “Reduced Blood Pressure: Was It Caused By Lung Muscle Training?” | >

An Introduction to Neuroinformatics

Details

The goal of brain imaging is to provide in-vivo measures of the human brain to better understand how the brain is structured, connected and functions.
In this talk, we will discuss how to analyze brain imaging data in order to make sense of the large amount of data that comes out of the scanner.

👤 **About the speaker**

[Dr. Camille Maumet](https://twitter.com/cmaumet) is a research scientist in neuroinformatics at Inria, Univ Rennes, CNRS, Inserm in Rennes, France.
Her research focuses on the variability of analytical pipelines and its impact on our ability to reuse brain imaging datasets.
She obtained her PhD in computer science at the University of Rennes on the analyses of clinical neuroimaging datasets in functional magnetic resonance imaging and.
arterial spin labelling. She was then a postdoctoral research fellow in the Institute of Digital Healthcare at the University of Warwick and the University of Oxford.
where she focused on meta-analyses and standards for neuroimaging data sharing. She is also an open science advocate.
involved in the development of more inclusive research practices and community-led research and participates in many collaborative efforts including Brainhack.
the INCF, and the Open Science Special Interest Group of the Organization for Human Brain Mapping that she chaired in 2020.
–
[Nipype Tutorial](https://miykael.github.io/nipype_tutorial/)
–
Annual Brain Imaging Events:

[OHBM Brainhack (Brain Hackathon) June 16–18](https://ohbm.github.io/hackathon2022/)[registration via](https://www.humanbrainmapping.org/i4a/ams/meetings/index.cfm…ageID=4073)

- [OHBM Open Science Room (Discussions around open science practices & brain imaging)](https://ohbm.github.io/osr2022/)

Continue reading “An Introduction to Neuroinformatics” | >